ERBB2 and breast carcinoma: Indeed, several HER-targeting antibodies and small molecule-type inhibitors (TKIs) have been developed, and the HER2-specific antibody trastuzumab has profoundly improved treatment outcome in HER2 overexpressing human breast cancer [3].